You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ND0612

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ND0612?

ND0612 is an investigational drug.

There have been 9 clinical trials for ND0612. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2016.

The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Quotient Clinical, and Michael J. Fox Foundation for Parkinson's Research.

There are twenty-three US patents protecting this investigational drug and one hundred and sixty-nine international patents.

Recent Clinical Trials for ND0612
A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).NeuroDerm Ltd.Phase 3
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsNeuroDerm Ltd.Phase 3
A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's DiseaseNeuroDerm Ltd.Phase 2

See all ND0612 clinical trials

Clinical Trial Summary for ND0612

Top disease conditions for ND0612
Top clinical trial sponsors for ND0612

See all ND0612 clinical trials

US Patents for ND0612

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ND0612   Start Trial Dopa decarboxylase inhibitor compositions NeuroDerm, Ltd. (Rehovot, IL)   Start Trial
ND0612   Start Trial Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof LobSor Pharmaceuticals Aktiebolag (Knivsta, SE)   Start Trial
ND0612   Start Trial Anti-nausea drug combinations   Start Trial
ND0612   Start Trial Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same Samyang Biopharmaceutical Corporation (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ND0612

Drugname Country Document Number Estimated Expiration Related US Patent
ND0612 Australia 2015228369 2034-03-13   Start Trial
ND0612 Canada 2942244 2034-03-13   Start Trial
ND0612 China 106413754 2034-03-13   Start Trial
ND0612 European Patent Office 3116475 2034-03-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.